Prospective Grant of Exclusive Patent License, 15184 [2017-06003]
Download as PDF
<![CDATA[
15184
Federal Register / Vol. 82, No. 57 / Monday, March 27, 2017 / Notices
regarding the reimbursement of
antidumping duties prior to liquidation
of the relevant entries during this
review period. Failure to comply with
this requirement may result in the
presumption that reimbursement of
antidumping duties occurred and the
subsequent assessment of doubled
antidumping duties.
Notification Regarding Administrative
Protective Order
This notice serves as the only
reminder to parties subject to the
administrative protective order (APO) of
their responsibility concerning the
disposition of proprietary information
disclosed under APO in accordance
with 19 CFR 351.305(a)(3). Timely
written notification of the return/
destruction of APO materials or
conversion to judicial protective order is
hereby requested. Failure to comply
with the regulations and terms of an
APO is a sanctionable violation.
This notice is published in
accordance with sections 751(a) and
777(i)(1) of the Act and 19 CFR
351.213(d)(4).
Dated: March 20, 2017.
Gary Taverman,
Acting Deputy Assistant Secretary for
Antidumping and Countervailing Duty
Operations.
DEPARTMENT OF COMMERCE
National Institute of Standards and
Technology
Prospective Grant of Exclusive Patent
License
National Institute of Standards
and Technology, Department of
Commerce.
ACTION: Notice; prospective grant of
exclusive patent license.
AGENCY:
The National Institute of
Standards and Technology (‘‘NIST’’),
U.S. Department of Commerce, is
contemplating the grant of an exclusive
license in the United States of America,
its territories, possessions and
commonwealths, to NIST’s interest in
the invention embodied in U.S. Patent
Application No. 62/302,855, titled
‘‘Prostate Cancer Detection Using
Western Blot Analysis,’’ (NIST Docket
No. 16–007) to McJimpsey
Biotechnologies, Inc. The grant of the
license would be for prostate cancer
detection.
FOR FURTHER INFORMATION CONTACT:
Donald Archer, National Institute of
asabaliauskas on DSK3SPTVN1PROD with NOTICES
18:02 Mar 24, 2017
Jkt 241001
[FR Doc. 2017–06003 Filed 3–24–17; 8:45 am]
BILLING CODE 3510–13–P
DEPARTMENT OF COMMERCE
Submission for OMB Review;
Comment Request
BILLING CODE 3510–DS–P
VerDate Sep<11>2014
Phillip Singerman,
Associate Director for Innovations and
Industry Services.
National Oceanic and Atmospheric
Administration
[FR Doc. 2017–05987 Filed 3–24–17; 8:45 am]
SUMMARY:
Standards and Technology, Technology
Partnerships Office, 100 Bureau Drive,
Stop 2200, Gaithersburg, MD 20899,
(301) 975–2522; donald.archer@nist.gov.
SUPPLEMENTARY INFORMATION: The
prospective exclusive license will be
royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7. The prospective
exclusive license may be granted unless,
within fifteen (15) days from the date of
this published Notice, NIST receives
written evidence and argument which
establish that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR 404.7. The Provisional Patent
Application was filed on March 3, 2016
and describes systems and methods for
detecting prostate cancer.
The Department of Commerce will
submit to the Office of Management and
Budget (OMB) for clearance the
following proposal for collection of
information under the provisions of the
Paperwork Reduction Act (44 U.S.C.
Chapter 35).
Agency: National Oceanic and
Atmospheric Administration (NOAA).
Title: Management and Oversight of
the National Estuarine Research Reserve
System.
OMB Control Number: 0648–0121.
Form Number(s): None.
Type of Request: Regular (extension of
a currently approved information
collection).
Number of Respondents: 75.
Average Hours per Response:
Management plan, 1800 hours; site
profile, 1800 hours; award application,
8 hours; award reports, 5 hours;
designations, 2000 hours; NEPA
documentation, 40 hours.
Burden Hours: 8,216.
Needs and Uses: The Coastal Zone
Management Act of 1972 (CZMA; 16
U.S.C. 1461 et seq.) provides for the
designation of estuarine research
reserves representative of various
regions and estuarine types in the
United States to provide opportunities
for long-term research, education and
interpretation. During the site selection
PO 00000
Frm 00006
Fmt 4703
Sfmt 4703
and designation process, information is
collected from states in order to prepare
a management plan and environmental
impact statement. Designated reserves
apply annually for operations funds by
submitting a work plan; subsequently
progress reports are required every six
months for the duration of the award.
Each reserve compiles an ecological
characterization or site profile to
describe the biological and physical
environment of the reserve, research to
date and research gaps. Reserves revise
their management plans every five
years. This information is required to
ensure that reserves are adhering to
regulations and that the reserves are in
keeping with the purpose for which
they were designated.
Affected Public: Not-for-profit
instituations; state, local or tribal
government.
Frequency: On occasion, semiannually and annually.
Respondent’s Obligation: Required to
obtain or retain benefits.
This information collection request
may be viewed at reginfo.gov. Follow
the instructions to view Department of
Commerce collections currently under
review by OMB.
Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to OIRA_Submission@
omb.eop.gov or fax to (202) 395–5806.
Dated: March 22, 2017.
Sarah Brabson,
NOAA PRA Clearance Officer.
[FR Doc. 2017–05973 Filed 3–24–17; 8:45 am]
BILLING CODE 3510–08–P
DEPARTMENT OF COMMERCE
National Oceanic and Atmospheric
Administration
RIN 0648–XF315
Mid-Atlantic Fishery Management
Council (MAFMC); Public Meeting
National Marine Fisheries
Service (NMFS), National Oceanic and
Atmospheric Administration (NOAA),
Commerce.
ACTION: Notice; public meeting.
AGENCY:
The Mid-Atlantic Fishery
Management Council’s (MAFMC)
Atlantic Surfclam and Ocean Quahog
Advisory Panel (AP) will hold a public
meeting.
DATES: The meeting will be held on
Tuesday, April 18, 2017, from 10 a.m.
to 4 p.m. For agenda details, see
SUPPLEMENTARY INFORMATION.
SUMMARY:
E:\FR\FM\27MRN1.SGM
27MRN1
]]>Agencies
[Federal Register Volume 82, Number 57 (Monday, March 27, 2017)]
[Notices]
[Page 15184]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-06003]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
National Institute of Standards and Technology
Prospective Grant of Exclusive Patent License
AGENCY: National Institute of Standards and Technology, Department of
Commerce.
ACTION: Notice; prospective grant of exclusive patent license.
-----------------------------------------------------------------------
SUMMARY: The National Institute of Standards and Technology (``NIST''),
U.S. Department of Commerce, is contemplating the grant of an exclusive
license in the United States of America, its territories, possessions
and commonwealths, to NIST's interest in the invention embodied in U.S.
Patent Application No. 62/302,855, titled ``Prostate Cancer Detection
Using Western Blot Analysis,'' (NIST Docket No. 16-007) to McJimpsey
Biotechnologies, Inc. The grant of the license would be for prostate
cancer detection.
FOR FURTHER INFORMATION CONTACT: Donald Archer, National Institute of
Standards and Technology, Technology Partnerships Office, 100 Bureau
Drive, Stop 2200, Gaithersburg, MD 20899, (301) 975-2522;
donald.archer@nist.gov.
SUPPLEMENTARY INFORMATION: The prospective exclusive license will be
royalty bearing and will comply with the terms and conditions of 35
U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be
granted unless, within fifteen (15) days from the date of this
published Notice, NIST receives written evidence and argument which
establish that the grant of the license would not be consistent with
the requirements of 35 U.S.C. 209 and 37 CFR 404.7. The Provisional
Patent Application was filed on March 3, 2016 and describes systems and
methods for detecting prostate cancer.
Phillip Singerman,
Associate Director for Innovations and Industry Services.
[FR Doc. 2017-06003 Filed 3-24-17; 8:45 am]
BILLING CODE 3510-13-P
